Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Structure of Lipids03:38

Structure of Lipids

Lipids include a diverse group of compounds that are largely nonpolar in nature. This is because they are hydrocarbons that include mostly nonpolar carbon-carbon or carbon-hydrogen bonds. Non-polar molecules are hydrophobic (“water fearing”), or insoluble in water. Lipids perform many different functions in a cell. Cells store energy for long-term use in the form of fats. Lipids also provide insulation from the environment for plants and animals. For example, they help keep aquatic birds and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

H<sub>2</sub>S signal enhances storage globulin hydrolysis, embryo supercooling and freezing tolerance of hydrated brassica (Brassica oleracea) seeds.

Cryo letters·2025
Same author

The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.

Multiple sclerosis and related disorders·2024
Same author

Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.

Journal of neurology·2023
Same author

The causal role of gut microbiota in development of osteoarthritis.

Osteoarthritis and cartilage·2021
Same author

[Malignant peripheral nerve sheath tumor of the heart: report of a case].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2021
Same author

Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial.

Multiple sclerosis journal - experimental, translational and clinical·2019

Related Experiment Video

Updated: May 15, 2026

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Polyunsaturated fatty acids in multiple sclerosis therapy.

S Wergeland1, Ø Torkildsen, L Bø

  • 1Department of Neurology, Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, Bergen, Norway. stig.wergeland@gmail.com

Acta Neurologica Scandinavica. Supplementum
|January 3, 2013
PubMed
Summary

Polyunsaturated fatty acids (PUFAs) show no proven benefit for multiple sclerosis (MS) patients. Randomized controlled trials found neither omega-3 nor omega-6 PUFAs improved clinical or MRI disease activity in MS.

More Related Videos

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: May 15, 2026

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

  • Neuroscience
  • Immunology
  • Nutritional Science

Background:

  • Epidemiological and uncontrolled studies suggest polyunsaturated fatty acids (PUFAs) may modify multiple sclerosis (MS) disease progression.
  • However, rigorous evidence from controlled trials is needed to confirm these potential benefits.

Purpose of the Study:

  • To systematically review evidence from animal models and randomized controlled trials (RCTs) regarding the therapeutic effects of PUFAs in MS.
  • To evaluate the impact of omega-3 and omega-6 fatty acids on MS disease activity.

Main Methods:

  • Searched PubMed and Medline for studies on PUFAs (e.g., eicosapentaenoic acid, docosahexaenoic acid, linoleic acid) and multiple sclerosis.
  • Included animal models (experimental autoimmune encephalomyelitis, cuprizone) and randomized controlled trials (RCTs).
  • Reviewed abstracts for relevance and content related to PUFA efficacy in MS.

Main Results:

  • Animal studies showed mixed results for omega-6 PUFAs, with some indication of effect.
  • RCTs found no beneficial effects of omega-6 PUFAs (linoleic acid, γ-linolenic acid) on clinical MS activity.
  • RCTs also showed no beneficial effects of omega-3 PUFAs (eicosapentaenoic acid, docosahexaenoic acid) on clinical or MRI disease activity in MS.

Conclusions:

  • Randomized controlled trials provide no evidence that omega-3 or omega-6 PUFA supplementation benefits MS patients.
  • PUFA interventions did not demonstrate improvements in relapse rate, disability progression, or MRI-detected disease activity in MS.